Journal of Clinical Medicine
Changes in Tacrolimus and Everolimus Trough Concentrations and Dose Requirements After Initiation and Discontinuation of Letermovir Prophylaxis in Kidney Transplant Recipients: A Single-Center Retrospective Study
By Junji Uchida, Shunji Nishide, Yuji Takeyama and 6 others.
Abstract
Background/Objectives: Letermovir is effective for cytomegalovirus (CMV) prophylaxis after kidney transplantation, but cytochrome P450 3A inhibition may alter tacrolimus and everolimus exposure. We evaluated changes in trough concentrations and dose requirements during letermovir initiation and discontinuation in de novo kidney transplant recipients.
Methods
This single-center retrospective observational study included 20 living-donor kidney transplant recipients with D+/R− or R+ CMV serostatus receiving everolimus-based reduced-tacrolimus immunosuppression and letermovir prophylaxis. Trough concentrations, daily doses, kidney allograft function, CMV outcomes, and safety were assessed descriptively.